Is rifaximin appropriate for secondary prophylaxis of recurrent diverticulitis in adults who have had at least two episodes in the past year?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rifaximin Should Not Be Used for Secondary Prophylaxis of Recurrent Diverticulitis

The American Gastroenterological Association (AGA) and American College of Physicians (ACP) both recommend against using rifaximin to prevent recurrent diverticulitis after acute uncomplicated episodes. This recommendation is based on insufficient evidence of efficacy, uncertain benefits, and consideration of costs and potential adverse events 1, 2.

Guideline-Based Recommendations

The 2015 AGA guideline explicitly states a conditional recommendation against rifaximin use after acute uncomplicated diverticulitis, citing very-low quality evidence 1. The evidence base consisted of only one unblinded study that was terminated early and showed a numerical but not statistically significant reduction in recurrence rates 1.

The 2022 ACP guideline reinforces this position, noting that evidence for rifaximin was insufficient to issue any recommendation, either for or against its use 2. The ACP Clinical Guidelines Committee did not find adequate data to support rifaximin for preventing recurrent diverticulitis.

The 2021 AGA Clinical Practice Update further emphasizes: "Patients with a history of diverticulitis should not be treated with rifaximin to prevent recurrent diverticulitis" 3.

Evidence Quality and Limitations

Why the Evidence Fails to Support Rifaximin:

  • Single terminated trial: The primary evidence comes from one unblinded study stopped prematurely, with results that did not reach statistical significance 1
  • Very low certainty: All major guidelines rate the evidence quality as "very low" or "insufficient" 1, 2
  • Cost considerations: Rifaximin is expensive, and the uncertain benefit does not justify routine use 1
  • Potential harms: While generally well-tolerated, rifaximin carries risks of adverse events and potential for antibiotic resistance 1

Research Studies Show Mixed Results:

While some observational studies suggest potential benefit 4, 5, 6, these are contradicted by more recent analyses. A 2023 systematic review found that for secondary prevention, rifaximin showed a risk difference of -24% (CI -47% to -2%), but with very high heterogeneity (I² 92%) and low-quality evidence 7. A 2026 post-hoc analysis actually found rifaximin associated with a higher hazard risk compared to no treatment 8.

FDA-Approved Indications

Rifaximin is NOT FDA-approved for diverticulitis prevention. The FDA-approved indications for rifaximin (XIFAXAN) are limited to 9:

  • Travelers' diarrhea caused by noninvasive E. coli
  • Reduction in risk of hepatic encephalopathy recurrence
  • Treatment of irritable bowel syndrome with diarrhea (IBS-D)

What Should Be Done Instead

For patients with recurrent diverticulitis (≥2 episodes in the past year):

  1. Avoid NSAIDs if possible (conditional recommendation) 1
  2. Consider high-fiber diet or fiber supplementation (conditional recommendation) 1
  3. Encourage vigorous physical activity (conditional recommendation) 1
  4. Do NOT use mesalamine (strong recommendation against) 1, 2
  5. Do NOT use probiotics (conditional recommendation against) 1

When to Consider Surgery:

Discuss elective sigmoid resection for patients with 2, 3:

  • Persistent symptoms lasting >3 months, OR
  • Frequent recurrences (≥3 episodes within 2 years), OR
  • Complicated diverticulitis

High-certainty evidence shows elective surgery reduces recurrence risk by approximately 21.5% (ARD -21.5%, CI -27% to -11%) in these high-risk populations 2. However, surgery carries perioperative complication rates of 1.4-5.5% 2.

Critical Caveats

  • The guideline recommendations specifically address acute uncomplicated diverticulitis; they do not apply to symptomatic uncomplicated diverticular disease (SUDD), which is a different clinical entity 1
  • Most complications occur with the first episode of diverticulitis, not recurrences 3
  • Risk of complicated diverticulitis actually decreases with subsequent episodes (OR 0.78,95% CI 0.62-0.98) 3
  • Approximately 20% of patients experience recurrence within 10 years, but the risk of emergency surgery is low (<5%) 1, 3

In your patient with two episodes in the past year, rifaximin should not be prescribed for secondary prophylaxis. Focus instead on lifestyle modifications (fiber, physical activity, NSAID avoidance) and consider discussing elective surgery if episodes are frequent or severe.

References

Research

One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.